Marie-Catherine Giarratana1, Ladan Kobari1, Hélène Lapillonne1, 2, David Chalmers1, 3, Laurent Kiger4, Thérèse Cynober5, Michael C Marden4, Henri Wajcman6
& Luc Douay1, 21
Laboratoire d'Hématologie EA1638, Université Paris VI, CHU Saint Antoine, 27 rue de Chaligny-75571 Paris Cedex 12, France.
2
Service d'Hématologie Biologique, Hôpital Armand Trousseau, Assistance Publique Hôpitaux de Paris, 26 avenue du Dr Netter-75571 Paris Cedex 12, France.
3
EFS Bourgogne Franche Comte, Boulevard Fleming BP 1937 Besançon 25290, France.
4
INSERM U473, 84 rue du Général Leclerc, 94276 Le Kremlin-Bicêtre Cedex, France.
5
Laboratoire d'Hématologie, Centre Hospitalier de Bicêtre, 84 rue du Général Leclerc, 94276 Le Kremlin-Bicêtre Cedex, France.
6
INSERM U468, Hôpital Henri Mondor, 94010 Créteil, France.
Correspondence should be addressed to Luc Douay luc.douay@trs.aphp.fr
106-fold) with 100% terminal differentiation into fully mature, functional RBCs. These cells survived in nonobese diabetic/severe combined immunodeficient mice, as do native RBCs. Our system for producing 'cultured RBCs' lends itself to a fundamental analysis of erythropoiesis and provides a simple in vitro model for studying important human viral or parasitic infections that target erythroid cells. Further development of large-scale production of cultured RBCs will have implications for gene therapy, blood transfusion and tropical medicine.
